Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AKBA stock, giving a Buy rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Akebia Therapeutics’ strategic initiatives and potential for growth. The partnership with DaVita, a leading dialysis provider in the U.S., is a significant strategic move that addresses key barriers to the adoption of Akebia’s product, Vafseo. This collaboration is expected to enhance clinical evidence and facilitate the adoption of Vafseo across the dialysis industry, as DaVita’s influence could encourage other large dialysis organizations to follow suit.
Moreover, the VOCAL trial with DaVita is designed to tackle the challenges of “protocolization” that have been identified by key opinion leaders. The trial’s focus on a three-times-weekly dosing regimen and the examination of red-blood-cell quality improvements further strengthen Vafseo’s value proposition. These efforts demonstrate Akebia’s proactive approach to overcoming industry challenges and could serve as a catalyst for broader adoption, reinforcing the Buy rating.
Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, Amarin, and Aquestive Therapeutics. According to TipRanks, Ruiz has an average return of -7.1% and a 36.67% success rate on recommended stocks.
In another report released on July 28, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.